抗炎药物作为潜在的抗微生物药物:一篇综述
Onyedika Emmanuel Okpala1, Johana Rondevaldova1, Ladislav Kokoska1
1Department of Crop Sciences and Agroforestry, Faculty of Tropical AgriSciences, Czech University of Life Sciences Prague, Prague, Czechia.
Frontiers in pharmacology
|April 23, 2025
概括
某些非类固醇抗炎药物 (NSAIDs) 具有抗菌性,这表明双重作用药物在治疗联合传染病和炎症疾病方面具有潜在的潜力. 需要进一步的临床试验来确认它们的有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 炎症 炎症是一种炎症.
背景情况:
- 治疗结合感染性和炎症性疾病往往需要多种药物,导致不良影响.
- 开发双作用药物对于改善患者的治疗结果和减少副作用至关重要.
- 某些抗炎药物表现出抗菌性质,为双重作用疗法提供了有前途的候选人.
研究的目的:
- 研究非类固醇抗炎药物 (NSAIDs) 的抗菌潜力,用于治疗结合感染和炎症疾病.
- 为了评估NSAIDs如ibuprofen,阿司匹林和celecoxib对各种细菌病原体的疗效.
主要方法:
- 在患有尿路感染 (UTI) 和蜂炎的患者中进行了NSAIDs的临床试验.
- 在体外和体内,NSAIDs的抗微生物活性被评估对一系列细菌菌株,包括抗生素耐药的细菌.
- 在受感染的动物模型中确定了生存率和最小抑制度 (MIC).
主要成果:
- 布洛芬在尿路感染患者中显示出症状缓解,在感染了Pseudomonas aeruginosa的小鼠中显示出显著的存活率,在体外对包括MRSA在内的阳性和阴性细菌具有强烈的活性.
- 奥拉诺芬,阿司匹林和切莱科西布也表现出显著的体外和/或体内微生物抗菌作用,对各种病原体,包括 Mycobacterium tuberculosis 和 Staphylococcus aureus.
- 无 NSAID 药物显示出有前途的广泛抗菌活性,MIC 值因药物和细菌物种而异.
结论:
- 一些NSAID具有显著的抗菌特性,使他们成为双重作用药物开发的有希望的候选人.
- 这些发现表明NSAID在治疗尿路感染,结核病和肌肉骨感染等感染方面的潜在治疗应用.
- 进一步的临床研究至关重要,以验证NSAIDs在实际临床使用中的抗菌疗效.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Combined Effects of Drugs: Synergism
3.6K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97


